ProfileGDS5678 / 1448297_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 80% 80% 83% 83% 79% 85% 79% 84% 86% 85% 85% 86% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5351179
GSM967853U87-EV human glioblastoma xenograft - Control 25.7009580
GSM967854U87-EV human glioblastoma xenograft - Control 35.6377380
GSM967855U87-EV human glioblastoma xenograft - Control 46.2297283
GSM967856U87-EV human glioblastoma xenograft - Control 56.1523583
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3893479
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.145285
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5337479
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2351584
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6204186
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3521485
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4317185
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.4829786
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2747285